Prostaglandin E2 promotes liver cancer cell growth by the upregulation of FUSE-binding protein 1 expression

International Journal of Oncology

Volumn 42, Issue 3, 2013, Pages 1093-1104

  Ma, Juan ^a   Chen, Meng ^a   Xia, Shu Kai ^a   Shu, Wei ^b   Guo, Yan ^a   Wang, Yao Hui ^c   Xu, Yan ^a   Bai, Xiao Ming ^a   Zhang, Li ^a   Zhang, Hai ^a   Zhang, Min ^a   Wang, Yi Pin ^a   Leng, Jing ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b Jiangsu Province Engineering Research Center of Stomatological Translational Medicine   (China)

^c Jiangsu Province Hospital   (China)

Author keywords

E prostanoid 3 receptor; FUSE binding protein 1; JTV1; Liver cancer; Prostaglandin E2

Indexed keywords

9 (TETRAHYDRO 2 FURYL)ADENINE; ADENYLATE CYCLASE INHIBITOR; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; FUSE BINDING PROTEIN 1; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PERTUSSIS TOXIN; PROSTAGLANDIN E RECEPTOR 3; PROSTAGLANDIN E2; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; SULPROSTONE; SYNAPSIN I; UNCLASSIFIED DRUG; 9 (TETRAHYDRO 2 FURYL) ADENINE; 9-(TETRAHYDRO-2-FURYL)-ADENINE; ABORTIVE AGENT; ADENINE; ADENYLATE CYCLASE; AIMP2 PROTEIN, HUMAN; CARRIER PROTEIN; CYCLIC AMP; DNA BINDING PROTEIN; DRUG DERIVATIVE; ENZYME INHIBITOR; FORSKOLIN; FUBP1 PROTEIN, HUMAN; HELICASE; ISOQUINOLINE DERIVATIVE; N (2 (4 BROMOCINNAMYLAMINO)ETHYL) 5 ISOQUINOLINESULFONAMIDE; N-(2-(4-BROMOCINNAMYLAMINO)ETHYL)-5-ISOQUINOLINESULFONAMIDE; PROSTAGLANDIN E RECEPTOR 4; PROTEIN KINASE INHIBITOR; PTGER3 PROTEIN, HUMAN; SMAD2 PROTEIN; SMAD2 PROTEIN, HUMAN; SMALL INTERFERING RNA; SULFONAMIDE;

ARTICLE; CANCER GROWTH; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIVER CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UBIQUITINATION; UPREGULATION; BIOSYNTHESIS; CELL PROLIFERATION; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; GENETICS; LIVER TUMOR; METABOLISM; PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL LINE;

ABORTIFACIENT AGENTS, NONSTEROIDAL; ADENINE; ADENYLATE CYCLASE; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIC AMP; DINOPROSTONE; DNA HELICASES; DNA-BINDING PROTEINS; ENZYME ACTIVATION; ENZYME INHIBITORS; FORSKOLIN; HUMANS; ISOQUINOLINES; LIVER NEOPLASMS; PERTUSSIS TOXIN; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; RECEPTORS, PROSTAGLANDIN E, EP3 SUBTYPE; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; RNA INTERFERENCE; RNA, SMALL INTERFERING; SMAD2 PROTEIN; SULFONAMIDES; UBIQUITINATION;

MLCS; MLOWN;

EID: 84873670244     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1782     Document Type: Article

References (67)

1. LeBlanc MM, Giguère S, Lester GD, Brauer K and Paccamonti DL: Relationship between infection, inflammation and premature parturition in mares with experimentally induced placentitis. Equine Vet J (Suppl) 41: 8-14, 2012.
2. Menter DG and Dubois RN: Prostaglandins in cancer cell adhesion, migration, and invasion. Int J Cell Biol 2012: 723419, 2012.
3. Granado-Serrano AB, Martín MÁ, Bravo L, Goya L and Ramos S: Quercetin attenuates TNF-induced inflammation in hepatic cells by inhibiting the NF-κB pathway. Nutr Cancer 4: 588-598, 2012.
4. Sasaki Y, Kamei D, Ishikawa Y, et al: Microsomal prostaglandin E synthase-1 is involved in multiple steps of colon carcinogenesis. Oncogene 24: 2943-2952, 2012.
5. Thiel A, Narko K, Heinonen M, et al: Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice. Int J Cancer 131: 1032-1041, 2012.
6. Hoellen F, Kelling K, Dittmer C, Diedrich K, Friedrich M and Thill M: Impact of cyclooxygenase-2 in breast cancer. Anticancer Res 12: 4359-4367, 2011.
7. Nadda N, Vaish V, Setia S and Sanyal SN: Angiostatic role of the selective cyclooxygenase-2 inhibitor etoricoxib (MK0663) in experimental lung cancer. Biomed Pharmacother 66: 474-483 2012.
8. Smith KA, Tong X, Abu-Yousif AO, Mikulec CC, Gottardi CJ, Fischer SM and Pelling JC: UVB radiation-induced β-catenin signaling is enhanced by COX-2 expression in keratinocytes. Mol Carcinog 51: 734-745, 2012.
9. Phutthaphadoong S, Yamada Y, Hirata A, et al: Chemopreventive effect of fermented brown rice and rice bran (FBRA) on the inflammation-related colorectal carcinogenesis in ApcMin/+ mice. Oncol Rep 1: 53-59, 2010.
10. Bai XM, Jiang H, Ding JX, et al: Prostaglandin E2 upregulates survivin expression via the EP1 receptor in hepatocellular carcinoma cells. Life Sci 86: 214-223, 2010.
11. Zhang L, Jiang L, Sun QY, Peng T, Lou KX, Liu NB and Leng J: Prostaglandin E2 enhances mitogenactivated protein kinase/Erk pathway in human cholangiocarcinoma cells: involvement of EP1 receptor, calcium and EGF receptors signaling. Mol Cell Biochem 305: 19-26, 2007. (Pubitemid 47517163)
12. Wu T: Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochim Biophys Acta 1775: 135-150, 2005. (Pubitemid 40982563)
13. Kotelevets L, Foudi N, Louedec L, Couvelard A, Chastre E and Norel X: A new mRNA splice variant coding for the human EP3-I receptor isoform. Prostaglandins Leukot Essent Fatty Acids 77: 195-201, 2007. (Pubitemid 350138422)
14. Regan JW, Bailey TJ, Donello JE, et al: Molecular cloning and expression of human EP3 receptors: evidence of three variants with differing carboxyl termini. Br J Pharmacol 112: 377-385, 1994. (Pubitemid 24172872)
15. Schmid A, Thierauch KH, Schleuning WD and Dinter H: Splice variants of the human EP3 receptor for prostaglandin E2. Eur J Biochem 228: 23-30, 1995.
16. Kotani M, Tanaka I, Ogawa Y, et al: Molecular cloning and expression of multiple isoforms of human prostaglandin E receptor EP3 subtype generated by alternative messenger RNA splicing: multiple second messenger systems and tissue-specific distributions. Mol Pharmacol 48: 869-879, 1995.
17. Kotani M, Tanaka I, Ogawa Y, et al: Multiple signal transduction pathways through two prostaglandin E receptor EP3 subtype isoforms expressed in human uterus. J Clin Endocrinol Metab 85: 4315-4322, 2000. (Pubitemid 32055393)
18. Israel DD and Regan JW: EP(3) prostanoid receptor isoforms utilize distinct mechanisms to regulate ERK 1/2 activation. Biochim Biophys Acta 4: 238-245, 2009.
19. Rydziel S, Delany AM and Canalis E: AU-rich elements in the collagenase 3 mRNA mediate stabilization of the transcript by cortisol in osteoblasts. J Biol Chem 279: 5397-5404, 2004. (Pubitemid 38220562)
20. Malz M, Weber A, Singer S, et al: Overexpression of far upstream element binding proteins: a mechanism regulating proliferation and migration in liver cancer cells. Hepatology 50: 1130-1139, 2009.
21. Weber A, Kristiansen I, Johannsen M, et al: The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer. BMC Cancer 8: 369, 2008.
22. Chung HJ, Liu J, Dundr M, Nie Z, Sanford S and Levens D: FBPs are calibrated molecular tools to adjust gene expression. Mol Cell Biol 26: 6584-6597, 2006. (Pubitemid 44277896)
23. Rabenhorst U, Beinoraviciute-Kellner R, Brezniceanu ML, et al: Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth. Hepatology 4: 1121-1129, 2009.
24. Andersen SS: Spindle assembly and the art of regulating microtubule dynamics by MAPs and Stathmin/Op18. Trends Cell Biol 10: 261-267, 2000. (Pubitemid 30387030)
25. Singer S, Malz M, Herpel E, Warth A, Bissinger M, Keith M, Muley T, Meister M, Hoffmann H, Penzel R, Gdynia G, Ehemann V, Schnabel PA, Kuner R, Huber P, Schirmacher P and Breuhahn K: Coordinated expression of stathmin family members by far upstream sequence element-binding protein-1 increases motility in non-small cell lung cancer. Cancer Res 6: 2234-2243, 2009.
26. He LS, Liu JH, Collins I, et al: Loss of FBP function arrests cellular proliferation and extinguishes c-myc expression. EMBO J 5: 1034-1044, 2000. (Pubitemid 30119828)
27. Liu J, Kouzine F, Nie Z, et al: The FUSE/FBP/FIR/TFIIH system is a molecular machine programming a pulse of c-myc expression. EMBO J 10: 2119-2130, 2006.
28. Avigan MI, Strober B and Levens D: A far upstream element stimulates c-myc expression in undifferentiated leukemia cells. J Biol Chem 30: 18538-18545, 1990.
29. Hsiao HH, Nath A, Lin CY, et al: Quantitative characterization of the interactions among c-myc transcriptional regulators FUSE, FBP, and FIR. Biochemistry 49: 4620-4634, 2010.
30. Wierstra I and Alves J: The c-myc promoter: still MysterY and challenge. Adv Cancer Res 99: 113-333, 2008. (Pubitemid 350137254)
31. Jang M, Park BC, Kang S, et al: Far upstream element-binding protein-1, a novel caspase ubstrate, acts as a cross-talker between apoptosis and the c-myc oncogene. Oncogene 28: 1529-1536, 2009.
32. Wang X, Avigan M and Norgren RB: FUSE-binding protein is developmentally regulated and is highly expressed in mouse and chicken embryonic brain. Neurosci Lett 252: 191-194, 1998. (Pubitemid 28400340)
33. Ko HS, Kim SW, Sriram SR, Dawson VL and Dawson TM: Identification of far upstream element-binding protein-1 as an authentic Parkin substrate. J Biol Chem 281: 16193-16196, 2006.
34. Duncan RD, Bazar L, Michelotti G, et al: A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes 8: 465-480, 1994. (Pubitemid 24071186)
35. Bazar L, Harris V, Sunitha I, Hartmann D and Avigan MI: A transactivator of c-myc is coordinately regulated with the proto-oncogene during cellular growth. Oncogene 10: 2229-2238, 1995.
36. Yamaki T, Endoh K, Miyahara M, et al: Prostaglandin E2 activates Src signaling in lung adenocarcinoma cell via EP3. Cancer Lett 214: 115-120, 2004. (Pubitemid 39141204)
37. Yutaka S, Mami T, Nobuo T, et al: Prostaglandin E receptor EP3 deficiency modifies tumor outcome in mouse two-stage skin carcinogenesis. Carcinogenesis 26: 2116-2122, 2005.
38. Finetti F, Solito R, Morbidelli L, Giachetti A, Ziche M and Donnini S: Prostaglandin E2 regulates angiogenesis via activation of fibroblast growth factor receptor-1. J Biol Chem 283: 2139-2146, 2008.
39. Gutierrez DV, Mark MD, Masseck O, et al: Optogenetic control of motor coordination by Gi/o protein-coupled vertebrate rhodopsin in cerebellar Purkinje cells. J Biol Chem 286: 25848-25858, 2011.
40. Deng J, Liu S, Zou L, Xu C, Geng B and Xu G: Lipolysis response to endoplasmic reticulum stress in adipose cells. J Biol Chem 287: 6240-6249. 2012.
41. McCarthy TL, Pham TH, Knoll BI and Centrella M: Prostaglandin E2 increases transforming growth factor-β type III receptor expression through CCAAT enhancer-binding protein d in osteoblasts. Mol Endocrinol 11: 2713-2724, 2007. (Pubitemid 350035153)
42. Massague J, Blain SW and Lo RS: TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103: 295-309, 2000.
43. Shi Y and Massague J: Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113: 685-700, 2003. (Pubitemid 36724933)
44. Akhurst RJ and Derynck R: TGF-beta signaling in cancer - a double-edged sword. Trends Cell Biol 11: S44-S51, 2001.
45. Derynck R, Akhurst RJ and Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129, 2001. (Pubitemid 32952643)
46. Wakefield LM and Roberts AB: Learning together: clinical skills teaching for medical and nursing students. Curr Opin Genet 12: 22-29, 2002.
47. Pierce DF Jr, Johnson, MD, et al: Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-beta 1. Genes Dev 7: 2308-2317, 1993. (Pubitemid 24003235)
48. Cui W, Fowlis DJ, Bryson S, et al: TGFbeta1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86: 531-542, 1996. (Pubitemid 26299485)
49. Bottinger EP, Jakubczak JL, Haines DC, Bagnall K and Wakefield LM: Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor β receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7, 12-dimethylbenz-[a]-anthracene. Cancer Res 57: 5564-5570, 1997. (Pubitemid 28006765)
50. Gorska AE, Joseph H, Derynck R, Moses HL and Serra R: Dominant-negative interference of the transforming growth factor beta type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice. Cell Growth Differ 9: 229-238, 1998. (Pubitemid 28354303)
51. Engle SJ, Hoying JB, Boivin GP, Ormsby I, Gartside PS and Doetschman T: Transforming growth factor beta1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 59: 3379-3386, 1999. (Pubitemid 29334496)
52. Zhu Y, Richardson JA, Parada LF and Graff JM: Smad3 mutant mice develop metastatic colorectal cancer. Cell 94: 703-714, 1998. (Pubitemid 28436003)
53. Xu X, Brodie SG, Yang X, et al: Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. Oncogene 19: 1868-1874, 2000. (Pubitemid 30219029)
54. Tang B, Bottinger EP, Jakowlew SB, et al: Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med 4: 802-807, 1998. (Pubitemid 28331021)
55. Han C, Demetris AJ, Liu Y, Shelhamer JH and Wu T: Transforming growth factor-β (TGF-β) activates cytosolic phospholipase A2a (cPLA2a)-mediated prostaglandin E2 (PGE)2/EP1 and peroxisome proliferator-activated receptor-γ (PPAR-γ)/Smad signaling pathways in human liver cancer cells. A novel mechanism for subversion of TGF-β-induced mitoinhibition. J Biol Chem 43: 44344-44354, 2004.
56. Markowitz SD, Itzkowitz SH and Berger BM: The effectiveness of colonoscopy in reducing mortality from colorectal cancer. Ann Intern Med 150: 816-817, 2009.
57. Chowdhury S, Howell GM, Rajput A, et al: Identification of a novel TGFβ/PKA signaling transduceome in mediating control of cell survival and metastasis in colon cancer. PLoS One 5: e19335, 2011.
58. Liu X, Sun S and Ostrom R: Fibrotic lung fibroblasts show blunted inhibition by cAMP due to deficient cAMP response element-binding protein phosphorylation. J Pharmacol Exp Ther 2: 678-687, 2005. (Pubitemid 41500733)
59. Schiller M, Verrecchia F and Mauviel A: Cyclic adenosine 3', 5', -monophosphate-elevating agents inhibit transforming growth factor-beta-induced SMAD-dependent transcription via a protein kinase A-dependent mechanism. Oncogene 22: 8881-8890, 2003. (Pubitemid 38021504)
60. Kim MJ, Park BJ, Kang YS, Kim HJ, Park JH and Kang JW: Downregulation of FUSE-binding protein and c-myc by tRNA synthetase cofactor p38 is required for lung cell differentiation. Nat Genet 34: 330-336, 2003. (Pubitemid 36792868)
61. Kim JY, Kang YS, Lee JW, Kim HJ, Ahn YH, Park H, Ko YG and Kim S: p38 is essential for the assembly and stability of macromolecular tRNA synthetase complex: implications for its physiological significance. Proc Natl Acad Sci USA 99: 7912-7916, 2002. (Pubitemid 34650979)
62. Liu J, Chung HJ, Vogt M, et al: JTV1 co-activates FBP to induce USP29 transcription and stabilize p53 in response to oxidative stress. EMBO J 30: 846-858, 2011.
63. Sampath P, Mazumder B, Seshadri V, et al: Noncanonical function of glutamyl-prolyl-tRNA synthetase: genespecific silencing of translation. Cell 119: 195-208, 2004. (Pubitemid 39360902)
64. Park SG, Kang YS, Ahn YH, et al: Dose-dependent biphasic activity of tRNA synthetase-associating factor, p43, in angiogenesis. J Biol Chem 277: 45243-45248, 2002. (Pubitemid 36159129)
65. Han JM, Park BJ, Park SG, et al: AIMP2/p38, the scaffold for the multi-tRNA synthetase complex, responds to genotoxic stresses via p53. Proc Natl Acad Sci USA 105: 11206-11211, 2008.
66. Corti O, Hampe C, Koutnikova H, et al: p38 subunit of the aminoacyl-tRNA synthetase complex is a Parkin substrate: linking protein biosynthesis and neurodegeneration. Hum Mol Genet 12: 1427-1437, 2003. (Pubitemid 36758455)
67. Ko HS, Coelln R, Sriram SR, et al: Accumulation of the authentic parkin substrate aminoacyl-tRNA synthetase cofactor, p38/JTV-1, leads to catecholaminergic cell death. J Neurosci 25: 7968-7978, 2005. (Pubitemid 41254399)